AGCJ
RPRX

Alden Global Capital (Jersey)’s Repros Therapeutics Inc. RPRX Stock Holding History

Alden Global Capital (Jersey)’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-154,000
Closed -$1.53M – 60
2014
Q4 		$1.53M Buy
+154,000
New +$1.31M 0.37% 54

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Alden Global Capital (Jersey)'s RPRX Position: Q1 2015 in Review

Alden Global Capital (Jersey) sold out of Repros Therapeutics Inc. (RPRX) in Q1 2015, closing a stake of 154,000 shares — an estimated $1.53M sold.

Alden Global Capital (Jersey) first reported a position in RPRX in Q4 2014 and held it in 1 quarter. The position peaked at $1.53M in Q4 2014. 72 funds tracked by Wall St. Rank hold RPRX as of Q1 2015.

  • Alden Global Capital (Jersey) reported no remaining Repros Therapeutics Inc. position as of Q1 2015 after selling out during the quarter.
  • Alden Global Capital (Jersey) sold 154,000 Repros Therapeutics Inc. shares in Q1 2015, an estimated $1.53M.
  • Alden Global Capital (Jersey) first reported a position in Repros Therapeutics Inc. in Q4 2014 and held it in 1 quarter.
  • Alden Global Capital (Jersey)'s Repros Therapeutics Inc. position peaked at $1.53M in Q4 2014.
  • 72 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2015.

Based on Alden Global Capital (Jersey)'s 13F filing for Q1 2015.